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Summary 
 
Heart failure (HF) affects approximately 23 million individuals worldwide and this number is 
increasing, due to an aging and growing population. Early detection of HF is crucial in the 
management of this debilitating disease. Current diagnostic methods for HF rely heavily on 
clinical imaging techniques and blood analysis, which makes them less than ideal for 
population-based screening purposes. Studies focusing on developing novel biomarkers for 
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HF have utilized various techniques and biological fluids, including urine and saliva. 
Promising results from these studies imply that these body fluids can be used in evaluating 
the clinical manifestation of HF and will one day be integrated into a clinical workflow and 
facilitate HF management.  
1. Introduction 
1.1. Heart Failure 
Cardiovascular Diseases (CVD) cover a board range of health conditions that affect the 
heart and blood vessels [1]. CVD was the number one cause of mortality in Australia in 2011, 
accounting for approximately 45,662 (31%) of all deaths [2]. The most common CVDs 
include coronary heart disease (CHD), stroke and heart failure (HF) [3]. HF is defined as the 
heart’s inability to pump sufficient blood flow to meet the body’s requirements. HF is one of 
the more severe types of CVDs. HF is not a single standalone disease, but instead is a 
complex syndrome affecting cardiac and skeletal muscle and renal functions [4]. HF’s 
abnormalities may include shortness of breath (at rest or during exercise), fatigue, fluid 
retention and irregular heart beat [4].  
HF affects approximately 23 million people globally [5], including an estimated 5.7 million 
Americans with 670,000 new cases of HF diagnosed per annum. A similar prevalence and 
incidence is also found in Europe [6,7]. In 2007, approximately 4,000 people in Australia 
died with HF as the main cause [8]. In other developed countries such as the United States 
and Canada, the trends were similar [8]. In the United States alone, in 2015, the healthcare 
cost as a result of HF was estimated to be USD $ 44.6 billion [6]. In Australia, over AUD $ 
7.6 million was spent on CVD management in 2008-09, of which 35% was accounted 
towards the management of risk factors associated with HF [9].  One of the reasons for this 
D
ow
nl
oa
de
d 
by
 [Q
ue
en
sla
nd
 U
niv
ers
ity
 of
 T
ec
hn
olo
gy
] a
t 1
6:1
0 2
4 J
an
ua
ry 
20
16
 
higher healthcare cost with the management of HF is due to the unavailability of early 
diagnostic methods [10].  
1.2. Epidemiology of Heart Failure 
  HF is becoming one of the most common diseases in the developed world, with 
approximately 1-2% of the western population affected by this disease [8]. In North America, 
approximately 6.2 million individuals are living with HF (2.5% prevalence) [6] with over 1.1 
million new cases reported every year [11,12]. In Europe, Murphy et al. reported a 
prevalence rate of 9.1% in Scotland within a population above 85 years of age [13], while in 
East Asian countries, HF prevalence ranges from 1.3 to 6.7% [14].  
Epidemiology data on HF within the developing world (emerging economies) is less 
complete. One report used assumptions based on an American study data and estimated the 
prevalence of HF to be 1.9% in India [15]. Scattered studies have been conducted across the 
Middle East, reporting HF prevalence similar to the western world [16-18]. In South 
America, HF contributed to 6.3% of total deaths in the population [19]. Globally, the 
outcomes of HF are generally very poor. In America, one out of nine deaths is related to HF, 
and the 5 year survival rate following diagnosis is approximately 50% [20]. Similar numbers 
are reported in England (47%) [21]. However, the mortality rates of HF in East Asian 
countries are low, ranging between 2.2-8.8%, as reported in several studies [22-25]. 
1.3. Pathophysiology of Heart Failure 
During the onset and progression of HF, a series of alterations in cardiac structure and 
function occur. In response to these alternations, certain substances including specific 
proteins, peptides, hormones and non-coding RNA such as microRNA will be produced to 
compensate for the cardiac irregularities leading to the development of HF. Some of these 
substances may be released into the circulation, and those related to cardio protective 
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mechanisms have the potential to be used as specific makers to diagnose and monitor HF 
[26].  The close association of these biomolecules and their relevance to HF makes them ideal 
targets.   
HF can be divided into two categories based on the volume of blood a heart pumps out 
(left ventricular ejection fraction (LVEF)); HF with preserved ejection fraction (HFpEF, also 
known as diastolic HF) and HF with reduced ejection fraction (HFrEF, also known as systolic 
HF) [4]. In a failing heart, the ejection fraction is affected by various factors such as the 
stiffness of the ventricle wall, the enlarged ventricle and a decrease in contraction ability. In 
HFrEF, the ventricles become stiff and thick, which sequentially causes a reduction of 
systolic volume. In HFpEF, the ventricles enlarge, leading to lower ejection function. 
HF is a complex set of abnormalities instead of a standalone disease, the pathophysiology 
of HF is relatively complicated. At the molecular level, HF is associated with incorrect 
intracellular calcium signalling [4]. Calcium ion (Ca2+) transport within cardiomyocytes 
involves a process called excitation-contraction (E-C) coupling.  In a normal healthy heart, 
the intracellular Ca2+ concentration (stored in the sarcoplasmic reticulum (SR)) is increased 
upon systole, and decreased upon diastole [4]. These processes are regulated by the 
transverse-axial tubular system located on the cardiomyocyte membrane. In a failing heart, 
the cardiomyocyte shape, structure and the components such as the transverse-axial tubular 
system may change compared to a normal healthy heart [27]. Reduced SR function may also 
lead to a reduction in total intracellular Ca2+ concentration during HF pathogenesis [28].  
Other abnormalities are also found in failing cardiomyocytes including increased calcium 
sensor activity, and alterations in intercellular signalling pathways and gene expression 
patterns [4].  
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At the functional level, the pathophysiology of HF involves hemodynamic responses 
which help the heart to adapt to its reduced ability to provide enough blood to the body. 
Increase in preload (Frank–Starling mechanism) [29] and greater contractility provided from 
myocardial hypertrophy help improve the cardiac performance initially [29]. However, these 
compensation mechanisms become maladaptive as HF progress.  The LV is the most 
common part of the heart to develop remodelling during the initial cardiac pathology and 
progression of HF [30].  LV wall thickness and mass increase is a common sign of LV 
remodelling. Another important remodelling event is the dilation of the ventricle. Both of 
these remodelling events are related to myocyte hypertrophy and reduce ventricular wall 
stress at the initial stage of HF. However, they eventually lead to further reduction of cardiac 
function [30]. Furthermore, these cardiac remodelling events are related to several biological 
processes and may change the expression pattern of certain biomolecules which have the 
potential to be used as biomarkers to monitor the onset and progression of cardiac 
remodelling.  
2. Current Diagnostic Methods 
The New York Heart Association (NYHA) classifies HF based on physical symptoms 
which allow physicians and health professionals to provide medical advice and treatment to 
HF patients [31]. This classification system places HF patients into four categories (NYHA I-
IV) based on their symptoms, mainly based on the degree of limitation in performing 
physical activity [31]. Currently, there is no gold standard for HF diagnosis due to the 
complexity of HF. There are some commonly used systems (such as “Framingham criteria”, 
“Boston criteria”, and “Duke criteria” [32-34]) for HF diagnosis which are based on a 
combination of patient medical history, physical examinations, and supported by routine 
clinical procedures and laboratory tests [35]. However, diagnosing HF using solely physical 
examination is very difficult because the clinical manifestations of HF are non-specific 
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[35,36]. Common symptoms of HF include dyspnoea, fatigue, dizziness and oedema which 
can also be found with other disease conditions [10]. This highlights the importance of 
identifying HF-specific biomolecules/biomarkers that can be used to diagnose and treat HF. 
2.1. Cardiac Imaging 
2.1.1. Echocardiography 
Echocardiogram is one of the most common techniques currently used in diagnosing 
HF. The sonogram of the heart can provide information about cardiac structure (e.g. cardiac 
wall thickness, chamber volume, geometry and mass) and cardiac function (e.g. valvular 
function, and left ventricular ejection fraction (LVEF)) [37]. This information provides the 
basis of HF diagnosis. The measurement of LVEF guided the differentiation of HFrEF and 
HFpEF, for which treatment options vary - certain medication including angiotensin-
converting enzyme inhibitors and beta-blockers show benefit in HFrEF, while currently there 
is no treatment proven to reduce the mortality in HFpEF [38]. Certain non-surgical devices, 
for example implantable defibrillators, can be applied to patients with HFrEF diagnosed by 
echocardiogram to manage the development of the disease. 
2.1.2. Electrocardiogram 
A standard 12 leads electrocardiogram (ECG) is often performed on patients with 
suspected HF. The ECG data reveals any abnormalities of the heart’s electrical conduction 
and rhythm. Important clinical evidence such as myocardium loss can be measured through 
ECG, which provides crucial information for treatment decisions [39]. For example, when 
ECG result indicates a patient has atrial fibrillation, anticoagulation and heart rate control 
should be applied. Left bundle branch block, another condition that can be detected through 
ECG, can be promptly treated with cardiac resynchronization therapy [38].  
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2.1.3. Chest X-ray 
Chest X-ray is routinely performed on patients with acute HF onset [38]. Chest X-ray 
is most useful diagnostically for excluding pulmonary conditions causing dyspnoea and 
fatigue. However, this technique is less frequently used in patients with no acute HF onset 
due to its lack of sensitivity for HF diagnosis [38]. 
2.1.4. Cardiac magnetic resonance 
Cardiac magnetic resonance (CMR) is a magnetic resonance imaging (MRI) 
technique specifically optimized for use with the cardiovascular system. CMR provides high 
quality image of the heart and thus can be used to assess the cardiac volume, mass and wall 
motion with high accuracy and reproducibility [38]. It is considered to be the gold standard 
for measuring the above mentioned cardiac parameters [38]. However, due to its lack of 
availability and high cost, CMR is less frequently used in a clinical setting to diagnose HF. 
The utility of CMR is also limited by certain types of cardiac complications. For example 
when atrial arrhythmia is presented in a patient, the accuracy of CMR is reduced [38].  
2.1.5. Cardiac Catheterization and Coronary Angiography 
Cardiac catheterization and coronary angiography examination provides information about 
the blood flow and structure of coronary artery by injecting contrast material into the 
coronary artery and imaging with X-ray [4]. They may be performed in patient with 
suspected myocardial ischemia since coronary artery bypass surgery may be required. 
However, due to the invasive nature of this procedure, non-invasive test of myocardial 
viability is often conducted before coronary angiography to reduce the risk of cardiac 
catheterization [40]. 
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2.2. Biochemistry Examination 
Standard blood biochemical tests are often performed in patients presenting with 
suspected HF symptoms. The concentrations of blood ions (e.g. sodium and potassium) are 
closely related to cardiac contraction [41]. Glomerular filtration rate, which can be estimated 
with serum level of endogenous filtration markers, is a measure of renal function, which is 
important to take into account when making decision about treatment [42]. As type 2 diabetes 
is a common confounding condition in HF patients [43], blood glucose level is also an 
important factor to consider when treating HF patients. 
2.2.1. Myocardial Insult Markers- Cardiac Troponins and ST2 
Cardiac troponin I (cTnI) and T (cTnT) have been established as strong indicators of 
myocardium damage [44,45]. In the onset of myocardial infarction, the loss of cells’ 
membrane and structural integrity may cause the leakage of cardiac troponins from the 
cytosol, and thus elevated serum levels of cardiac troponins can be observed 4 to 6 hours 
after the onset of cardiac tissue damage [44]. Cardiac troponins have been used as diagnostic 
biomarkers in a clinical setting for the diagnosis and management of acute coronary 
syndrome (ACS) especially since assay sensitivity has been improved in recent years [46]. As 
myocardial infraction is a major risk factor for the development of HF, the association 
between cardiac troponins and HF have also been investigated. A study by La Vecchia et al 
found that cTnI was significantly elevated in HF patients compared to healthy controls and its 
levels also correlated with disease severity and reduced LVEF [47]. A follow-up study 
revealed that cTnI can predict one-year motility in acute HF patients [48]. However, this 
study also showed that the diagnostic performance of cTnI was not optimal, as the area under 
the ROC curve was 0.78 [48]. 
Interleukin 1 receptor-like 1 (IL1RL1), commonly referred to as ST2, is currently 
used as a prognostic biomarker for HF, and its concentration correlates with HF disease 
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severity [49,50]. ST2 has two isoforms: a soluble (sST2) form and membrane-bound receptor 
form (ST2L) [51]. The ligand for ST2 is interleukin-33 (IL-33), which is a cytokine [52]. IL-
33 binds to ST2L, which elicits maladaptive pro-hypertrophic and pro-fibrotic responses to 
mechanical stretch and stress [53]. sST2 acts as a decoy ligand and competitively binds to IL-
33 and decreases the binding of ST2L and IL-33. This interaction diminishes the ST2L/IL-33 
system’s cardioprotective effects [54]. Therefore, elevated concentrations of sST2 correlate 
with the cardiomyocytes’ inability to prevent injury. A recent study has shown that ST2 
outperforms BNP in terms of diagnostic specificity for acute onset of HF [55]. At the optimal 
cut-off, ST2 has a sensitivity of 73.5% and a specificity of 79.6% to detect acute HF [55]. 
Since ST2 is physiologically independent of natriuretic peptides, it is proposed that 
measuring ST2 and BNP/NT-proBNP at the same time may provide more comprehensive 
information about the underlying pathogenesis of HF [55]. 
 
2.2.2. Neurohormone Activation Marker- Natriuretic peptides 
Natriuretic peptides, which include B-type natriuretic peptide (BNP), are molecules 
secreted from cardiomyocytes in response to ventricular wall stress and ischemia. 
Cardiomyocytes secrete proBNP [1-108 AA], which is cleaved by serine proteases (furin and 
corin) to NT-proBNP (1-76 AA) and BNP (77-108 AA) [56]. The bioactive BNP can reduce 
the systemic blood volume by increasing the rate of diuresis, thus replenish the pumping 
ability of the failing heart [57]. BNP testing has become a gold standard in HF diagnosis for 
its ability to separate patient with chronic HF and without chronic HF [58]. NT-proBNP on 
the other hand, is also a useful biomolecule to detect the presence of diastolic dysfunction in 
patients suspected of HF [59]. Maisel et al., demonstrated that BNP can be used to diagnose 
congestive HF in patients with acute dyspnoea in conjunction with other clinical information 
[60], Lainchbury  et al. further reported that both BNP and NT-proBNP levels are useful in 
D
ow
nl
oa
de
d 
by
 [Q
ue
en
sla
nd
 U
niv
ers
ity
 of
 T
ec
hn
olo
gy
] a
t 1
6:1
0 2
4 J
an
ua
ry 
20
16
 
diagnosing HF in patients with acute dyspnoea [61]. A study has reported the sensitivity and 
specificity of BNP and NT-proBNP for HF at an optimal cut-off point to be  80% and 86% 
for BNP and 87% and 81% for NT-proBNP respectively [62].  Since NT-proBNP is more 
stable than BNP in the circulation, it is more favourable to measure NT-proBNP for the 
diagnosis of HF [63,64]. Studies have also shown a positive correlation between plasma BNP 
and NT-proBNP levels with HF severity [65].  
Serval point-of-care BNP and NT-proBNP assays, including Alere Triage® 
system,[66], ADVIA Centaur XP Immunoassay System [67], iSTAT system [68] and 
Elecsys® system [69], have been developed and used in a clinical setting to assist in the 
diagnosis of HF. The overall diagnostic performance of BNP across 31 independent clinical 
trials was estimated to be 90% and 77% in terms of sensitivity and specificity respectively, 
the figures for NT-proBNP were 90% and 74% respectively [70]. The level of NT-proBNP 
has also shown to be useful in terms of guiding the treatment for patients with chronic 
symptomatic HF. A clinical trial has demonstrated that three-year mortality rate for patients 
who receive NT-proBNP guided treatment (15.5%) was approximately half as high compared 
with patients who receive intensive clinical management (30.9%) and usual care (31.3%) 
[71]. The prognostic value of natriuretic peptides measurement was also explored. 
Bettencourt P et al. has shown that HF patients’ NT-proBNP level at hospital discharge can 
predict readmission and death within 6 months [72]. However, the accuracy and reliability of 
these peptide measurements for HF diagnosis is still controversial. It has been reported that 
NT-proBNP is present in various forms in blood and has shown to exhibit large patient-to-
patient variations [73]. There is still no standardized laboratory method for detecting 
natriuretic peptides, making it hard to compare across multiple platforms. The levels of 
natriuretic peptides are also affected by factors other than cardiac function (e.g. renal failure 
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[42]), which has further hindered the acceptance of BNP/NT-proBNP testing as a standard 
HF diagnostic test. 
2.2.3. Cardiac Remodeling Marker- Galectin-3  
Galectin-3 is a glycoprotein-binding, 26 kDa lectin family protein secreted by 
activated cardiac macrophages [74]. Previous studies have demonstrated that galectin-3 is 
involved in cell adhesion, activation, growth and differentiation [75]. It is reported that 
galectins can activate a number of cellular processes such as inflammation and fibrosis by 
binding to glycans and other proteins on cell surfaces [76-78]. Sharma et al. reported that 
galectin-3 was upregulated in the heart tissue in a HF animal model [79]. It has also been 
found that elevated galectin-3 levels are associated with poorer prognosis either alone [80] or 
in combination with BNP [81]. In addition to galectin-3 involvement in cardiac remodelling, 
galectin-3 also plays important roles in various types of cancer [82], the broad biological role 
of galectin-3 potentially lower its diagnostic specificity for HF. 
A commercial galectin-3 assay (Galectin-3 assay, BG Medicine, MA, USA) was 
introduced in 2013. The analytical performance of this commercial assay is  stable and 
reproducible (with coefficients of variations of <15% across multiple test concentrations) 
[83]. When used in a high throughput platform (ARCHITECT, Abbott Laboratories, IL, 
USA) this assay showed great potential for prognosis in HF patients. However, the diagnostic 
utility of galectin-3 as a biomarker for HF is still under investigation. One study has 
demonstrated that plasma galectin-3 levels have a sensitivity of 94.3% and a specificity of 
65.1% at the optimal cut-off point when used for HF diagnosis [84]. Further study with a 
larger study cohorts is needed to reveal the true diagnostic utility of galectin-3.  
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2.3. Other Currently Used Examinations 
2.3.1. Physical examination 
Since  HF symptoms are non-specific, physical exercise testing is usually used to 
distinguish between people suffering from dyspnoea and fatigue [85]. For example, when a 
person is suspected of having HF presents with dyspnoea, then he/she undergoes vigorous 
exercise testing and oxygen pulse measurement (oxygen uptake divided by heart rate). 
Patients with pulmonary disease presenting with the same symptoms will have normal 
oxygen pulse whilst patients with HF will show significant reductions in oxygen pulse l [85]. 
A more accurate diagnosis can be delivered to patients when combining physical examination 
coupled with other biochemical and clinical test results [86]. 
2.3.2. Endomyocardial biopsy 
Other invasive diagnostic methods such as endomyocardial biopsies are sometimes 
needed to confirm myocardial dysfunction [38]. However, due to the potential risk inherent in 
performing endomyocardial biopsy (e.g. ventricular or supraventricular arrhythmias, heart 
block, pneumothorax, puncture of central arteries and pulmonary embolization), the necessity 
of myocardial dysfunction in HF diagnosis still remains controversial [87]. 
2.4.  Limitations of Current Diagnostic Methods 
As mentioned above, the diagnostic methods currently used in a clinical setting have their 
shortcomings. The lack of specificity, sensitivity and accessibility of these methods has 
limited the utility of these methods in the early screening/diagnostic setting. One of the 
biggest clinical challenges for managing HF today is the lack of early screening/diagnostic 
methods to evaluate and assess at risk population groups [88]. This is in part due to the fact 
that early stage HF may be masked by other underlying conditions [10]. Early detection of 
HF either through “screening programs” or in general practice settings would allow 
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preventative strategies to be implemented before symptoms appear, improve patients’ 
prognoses, prevent further complications, and reduce pressure on health-care systems through 
a reduction in chronic HF episodes.  
One of the largest clinical trials currently being carried out in Australia is the 
SCREEN-HF longitudinal trial coordinated by the University of Monash, Australia. The 
primary objective of this trial is to identify at risk individuals for developing HF.  This study 
evaluates the use of biomarkers for stratification of risk for HF and other cardiovascular 
events.   Through this trial, we will be able to identify and screen individuals within our 
community in an asymptomatic state. Currently, there are no early screen methods in place to 
identify at risk individuals.  A typical HF diagnosis may consist of several of the above 
mentioned invasive and non-invasive examination methods. At the same time, other HF risk 
factors may also be taken into consideration such as family history of cardiovascular diseases, 
the status of smoking, dietary, obesity, exercise, blood pressure and diabetes. The current 
diagnostic methods are mostly blood based or image based, which require the presence of 
health care professionals in order to conduct the tests. This poses challenges for conducting 
early screening programs utilising blood-based assays for HF, especially in rural and remote 
areas where the access of ambulatory care is limited.  This means that there should be 
alternative approaches or strategies for the early diagnosis of HF with in the general 
population.  
2.5. Novel Biomarker discovery for HF 
Novel approaches have been proposed to address the above mentioned limitations to 
current HF diagnosis and management. These new methods focus on investigating the 
alternate use of biomarkers that is established for other conditions than HF, utilizing non-
traditional diagnostic biofluids (e.g. urine and saliva) and investigating novel targets of HF 
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(genomic and/or proteomic profiles). In this section we will discuss the novel biomarkers for 
HF still  in a research phase. 
2.5.1. Biomarker Repositioning 
HF is a complex condition which affects several biological processes. Biomarkers 
which have previously been identified in other diseases and conditions may therefore have 
the potential to be repositioned for use in HF diagnosis. Fibroblast growth factor 23 (FGF23) 
is a member of fibroblast growth factor family and has been shown to be associated with 
phosphate and calcium metabolism in the kidney [89]. A Recent study has shown that serum 
levels of FGF23 are correlated with HF disease severity in patients with chronic HF [90]. It 
has also been shown that its level is an independent predictor of HF incidence in individuals 
over the age of 65 years [91]. However, due to its role in regulation of mineral metabolism in 
the kidney and its relation with kidney diseases [92], further study is needed to fully evaluate 
its clinical specificity for HF. 
Syndecan-1 is a highly glycosylated protein which is involved in cell-matrix 
interactions; inflammation, fibrosis, and cardiac remodelling [93]. It has been previously 
associated with the development of several types of cancer [94-96]. A recent study has also 
found that syndecan-1 demonstrates similar prognostic value for HF and has significant 
correlation with other biomarkers that are related to cardiac remodelling (galectin-3 and ST2) 
[97]. However, the data on the comparison between the performance of syndecan-1 and other 
established remodelling biomarkers is still lacking.  
Inflammation plays an important role in atherosclerosis, which is a risk factor for HF 
[98]. C-Reactive Protein (CRP), an inflammation marker found in human plasma, has been 
documented to be increased in HF patients. Several studies have shown CRP is a strong and 
independent predictor of HF mortality and morbidity [99,100]. A recent study has also 
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demonstrated that CRP is significantly elevated in HF patients compared to healthy controls 
and its abundance correlates with NYHA classes [101]. Receiver Operative Characteristic 
(ROC) curve analysis showed a good diagnostic performance, with an area under curve of 
0.83 [101]. However, due to the fact the CRP is a non-specific inflammatory marker; the use 
of CRP in clinical HF diagnosis is limited. In the American Heart Association Guideline for 
Assessment of Cardiovascular Risk in Asymptomatic Adults it is suggested that measuring 
CRP is only beneficial in older patients (age>50) with no severe inflammatory conditions, 
renal dysfunction and diabetes [102].  
Carbohydrate antigen 125 (CA-125), also known as cancer antigen 125, is an 
established tumour marker for ovarian cancer [103] and breast cancer [104]. This heavily 
glycosylated mucin family protein is expressed on the surface of ovarian cancer cells as well 
as on some normal epithelial cells [105]. CA-125 has been used clinically to monitor ovarian 
cancer progression [106]. The biological role of CA-125 in cancer is still not fully 
understood, but studies have shown that CA-125 may facilitate cancer cell metastasis [107]. 
CA-125 is also found to be elevated in patients experiencing cardiac dysfunction. It was 
found that the serum level of CA-125 was elevated in chronic HF patients and that CA-125 
levels are positively correlated with disease severity [108]. Studies have also shown that CA-
125 is a specific binding partner of galectin-3 [109] and the measurement of these two 
biomarkers provides strong prognostic value in HF patients [110]. Further investigations are 
required to determine the clinical utility of CA-125 in HF diagnosis especially regarding its 
biological relevance to the pathogenesis of HF.  
Similar to CA125, HE4, a biomarker currently used to monitor the recurrence of 
progression of ovarian cancer, was shown to have a strong correlation with HF severity [111]. 
In the study conducted by de Boer et al. the plasma levels of HE4 was shown to have a 
significant correlation with other established HF biomarkers (e.g. BNP, NT-proBNP and 
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galectin-3) and  could improve the stratification of HF patients when combined with these 
established HF biomarkers [111]. As HE4 is not a heart tissue specific biomarker, the 
biological role of HE4 in HF is still elusive. Clinical trials to address its potential clinical 
utility would be worthwhile.  
2.5.2. Heart Failure diagnosis using urinary biomarkers 
Urine has been extensively used as an additional diagnostic medium in the past in 
particularly for diseases that are closely related to the urinary tract system [112]. Since the 
production of urine is essentially the ultrafiltration of blood, urine is also used for diagnostic 
and monitoring of systemic diseases [113,114]. 
Recent developments in HF pathophysiology have linked HF with renal function [115]. It 
was found that worsening renal function and kidney injury are connected with poor prognosis 
of HF patients [116]. Several novel urinary proteins that are associated with kidney injury 
have also been found in HF. The urinary level of acute kidney injury markers, N-acetyl-β-D-
glucosaminidase (NAG), Kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-
associated lipocalin (NGAL), are elevated in HF patients compared to matching healthy 
population [117]. The clinical usefulness of these markers in HF is still to be established. 
Several traditional HF biomarkers (e.g. creatinine [118]) were tested in urine since these 
small molecules can be freely filtered through glomeruli into urine. Creatinine and cystatin C, 
which were traditionally used in serum to estimate the glomerular filtration rate, have been 
investigated in urine and found to provide useful information on renal function in HF patients 
[118,119]. NT-proBNP, a highly sensitive HF marker (see section 2.2.1), was also found in 
urine and provided acceptable diagnostic values [120]. Even though plasma NT-proBNP 
levels still demonstratbetter diagnostic performance [120], further investigation into the 
clinical utility of urinary NT-proBNP in HF patients may still be rewarding.  
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2.5.3. Heart Failure diagnosis using salivary biomarkers 
Human saliva contains a large number of circulating proteins and peptides that can serve 
as indicators of the body's health and wellbeing [121]. Saliva is a plasma ultra-filtrate and 
contains a wide spectrum of biomolecules that are synthesized either by salivary glands or 
transported from blood capillaries into salivary acini cells. Saliva is produced by salivary 
acini cells and secreted into ducts where modifications of peptides/proteins occur along the 
ducts [122]. Human saliva contains more than 2000 unique proteins and ~20% of these 
proteins are also present in blood, demonstrating its clinical potential for detecting systemic 
events [123,124]. Although many analytes are present in saliva at concentrations 100 to 1000 
fold lower than in blood, the development of sensitive detection techniques can enable the 
detection of these molecules in saliva [125]. These detection methods can often be 
incorporated into automated equipment which allows high through-put and ease-of-use 
measurements of these biomarkers in saliva. 
Saliva has been championed as the diagnostic fluid of the future over blood and urine due 
to its numerous advantages [126]. Saliva specimen collection is straightforward, non-
invasive, safe and painless. Humans produce 500-1500 mL of saliva per day [127], making it 
an ideal medium to collect for screening proposes where minimal sample processing  is 
required. The speed and simplicity of collection, as well as the ability to collect multiple 
samples from an individual and straightforward uncomplicated sample collection reduces the 
risk of sample contamination. Importantly, saliva collection does not require professionals 
such as doctors and nurses to collect samples, with relatively low risk of contracting 
infectious microorganisms to the person collecting samples. It minimizes cost and facilitates 
repeat collection at multiple time points. It also means that saliva testing can be performed by 
patients or care givers at home, reducing the need for clinic or hospital visits and greatly 
facilitating self-management in disease monitoring, thereby significantly reducing the cost to 
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the healthcare system and the patient. Together, these factors significantly reduce logistical 
problems for large-scale collection in population-based screening studies and facilitate saliva 
sample collection in remote or challenging environments [121].  
Punyadeera et al. have demonstrated the utility of saliva as a medium for HF diagnosis. 
The inflammation biomarker CRP was detected in saliva samples of heathy controls as well 
as ischemic heart disease (IHD) patients, with the levels of salivary CRP significantly 
elevated in IHD patients [128]. A strong and positive correlation (Pearson r=0.92, p<0.0001) 
was also observed in CRP levels between serum and saliva, demonstrating the link between 
blood and saliva [128]. Furthermore, Foo et al., reported that NT-proBNP levels were 
significantly elevated in saliva collected from HF patients compared with controls [129]. It 
was found that in the HF patient cohort, NT-proBNP levels ranged from 18.3 to 748.7 pg/mL 
with a median of 76.8 pg/mL. Salivary NT-proBNP was not detected in healthy controls even 
when using a high sensitive assay (limit of detection: <16 pg/mL). Even though the 
participant number in this study was relatively small with 45 HF patients and 40 healthy 
controls, the potential of using saliva to diagnose HF was clearly demonstrated  [129]. 
Furthermore, a study investigating endothelin levels in saliva as a potential diagnostic 
biomarker has shown that endothelin levels were elevated by two to six-fold in HF patients’ 
saliva compared to healthy controls (p=0.005) and its level also increased incrementally 
through each NYHA classes (ANOVA p<0.05) [130]. A recent study has also demonstrated 
that both endothelin isoforms (endothelin-1 and endothelin-2) showed strong positive 
correlations between salivary levels and plasma levels [131], stressing the biological 
relevance of identifying and quantifying salivary biomarkers in HF diagnosis. 
The development of high sensitive detection techniques enables the utilization of saliva as 
a novel non-invasive diagnostic medium to detect not only HF but many more systemic 
diseases. For example, FDA has approved point-of-care diagnostic kit for detecting HIV in 
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AIDs patients and or at risk individuals [132]. The potential of using saliva in HF diagnosis 
has been demonstrated in a number of studies, and further investigations into its clinical 
usefulness are needed to enable the development of early diagnostic/screening programs 
utilizing saliva as a diagnostic medium. 
2.5.4. Proteome-wide approach 
The traditional biomarker discovery approach focus on single or a limited number of 
targets that are known to be involved in HF pathophysiology. This approach may overlook 
potential markers that are not directly involved in HF development or those that have not yet 
been documented. Recent developments in proteomics technologies have enabled whole 
proteome profiling of body fluids and tissues as a mean to overcome this limitation. By 
investigating the proteome of biological samples from HF patients, novel protein biomarkers 
may be discovered, validated, verified by other measurement techniques, and incorporated 
into clinical workflows. 
Early animal model studies utilizing two-dimensional gel electrophoresis showed the 
potential of proteomic profiling for HF using blood as a medium [133]. Gel-based proteomics 
profiling of CVD patients samples (blood or tissue) also provided useful information on the 
differential expression of a number of proteins, including blood coagulation factors, protease 
inhibitors and cardiac troponin [134,135]. However, the lack of reproducibility and sensitivity 
has limited the practicality of this technique. In contrast, recent advances in mass 
spectrometry (MS) technology have enabled in-depth and accurate analysis of 
proteins/peptides in body fluids. By using surface enhanced laser desorption ionisation time-
of-flight mass spectrometry (SELDI-TOF-MS), Paul et al. identified 6 novel biomarkers 
when comparing the proteomics profile of 78 HFrEF patients and 45 healthy controls [136]. 
In their follow-up trial, 5 out of 6 of these biomarkers also demonstrated prognostic value, 
showcasing the power of proteomic profiling combined with MS analysis. Mebazaa et al. 
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used a similar approach and targeted the low abundant proteins in plasma samples [137]. 
They discovered 49 potential markers in a small cohort comparison study (10 HF patients vs. 
10 healthy controls) using MS. They then validated the diagnostic performance of their panel 
with a target multiplexing immunoassay approach with a larger cohort (80 stable chronic HF 
patients, 147 patients with dyspnoea from cardiac and non-cardiac origin and 40 healthy 
controls). Quiescin Q6 was identified as a specific HF biomarker with a relatively high 
diagnostic performance (area under ROC curve=0.86). Even though the current literature 
does not directly link Quiescin Q6 with HF, the authors proposed that the disulfide bridge 
formation ability of Quiescin Q6 is involved with BNP activation [137].  Another powerful 
capability of proteomics profiling using MS is that it can identify post translation 
modifications (PTMs) of proteins without prior knowledge of their presence. As PTMs are 
important regulators of many biological functions, investigating PTMs is crucial to truly 
comprehend the biological relevance of biomarkers. By using different enrichment 
techniques, researchers were able to enrich peptides with specific PTMs. Phosphorylation and 
S-nitrosylation sites of a number of cardiac biomarkers were identified using various 
enrichment techniques [138,139]. Protein levels of polymorphisms (modifications of amino 
acid sequence) can also be identified using MS approaches. Peng et al. successfully identified 
five different isoforms of tropomyosin in human heart [140].  
 
2.5.5. Genetic biomarkers in heart failure 
HF diagnosis using genetic biomarkers has gained attention in the recent years.  It is 
known that HF can be caused by mutations in certain genes that encode cardiac regulatory 
proteins [141]. Genetic and epigenetic biomarkers (DNA/RNA/mRNA/miRNA) are 
interesting targets to detect such alterations. Even though a small percentage of HF patients 
display gene mutations these contribute greatly to mortality and morbidity, especially in 
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young HF patients [142]. Several gene mutations are associated with HF, including TNNI3 
(encodes cardiac troponin I) [143], TNNT2 (encodes cardiac troponin T) [144] and TTN 
(encodes titin) [145]. These mutations may alter cardiac structure, signal transduction and 
cardiac contractility making them important targets for diagnostic and treatment purposes  
Using heart tissue, researchers were able to identify genes that are differentially expressed 
in HF. Liu et al. compared the genomic profiling from heart tissue of healthy controls, 
ischemic and non-ischemic HF patients using microarrays [146]. Bioinformatics analysis 
revealed that among 426 differentially expressed genes, regulation of programmed cell death 
is the most common function. RNA sequencing was also used in a study of HF genomics. 
This study showed it is possible to distinguish HF patients and healthy controls using RNA 
sequencing data [147].  
MicroRNAs are small RNAs that are small, non-coding RNAs with regulatory functions 
including controlling gene expression of protein coding genes.  A recent review article by 
Oliveira-Carvalho et al. summarised studies investigating the role of microRNA in HF [148]. 
In these studies, a total of 24 microRNAs were found to be upregulated in HF patients and 13 
microRNAs were found to be downregulated [149]. In order to investigate the roles of 
microRNA for diagnostic purposes, microRNA expression levels in body fluid were also 
investigated.  A study conducted by Ellis et al. investigated the diagnostic potential of 7 
previously described differentially expressed microRNAs in the heart tissue of HF patients 
compared to non-HF heart tissue [150]. The microRNAs displayed inferior diagnostic 
performance when compared to the proteins NT-proBNP and cardiac troponin T, but by 
combining the microRNAs with NT-proBNP, the diagnostic performance of NT-proBNP 
improved by 4%.  It is clear that the genomics aspect of HF needs to be considered when 
discovering novel HF biomarkers. However, due to their cost and complicated data analysis, 
the application of genomic biomarkers in clinical setting is still restricted. 
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Expert Commentary 
One of the biggest clinical challenges that cardiologists are constantly faced with is the 
lack of early screening/diagnostic methods for HF [88]. This may be due to the fact that early 
stage HF may be unspecific and that the symptoms are common to other diseases [10]. 
Efforts have been made to address this problem by investigating new body fluids such as 
saliva and urine as well as to develop novel diagnostic biomarkers. Serval biomarkers have 
shown great potential for early diagnosis of HF. Even though, there has been no universally 
accepted biomarker, natriuretic peptides are one of the most specific biomarkers for HF. 
Combined with other novel biomarkers (ST2, Galectin etc.), BNP/NT-proBNP tests were 
shown to have high diagnostic performance for HF. Biomarkers detected in saliva and urine 
have shown great potential to be translated into clinical settings.  
Five-year View 
With the advancement of detection technologies, more and more potential biomarkers 
will be identified for HF diagnosis. However, in order for these biomarkers to be used in a 
clinical setting, the diagnostic performance of these biomarkers needs to be validated in 
randomised, double-blinded large population based studies [151]. As an example, when 
developing a screening biomarker panel to discriminate at risk individuals who will develop 
HF later in their lives, it is important to develop a low cost assay with high specificity and 
relatively higher negative predictive value. Comprehensive studies that combine multiple 
levels of evidence (e.g. proteomics, genomics and metabolomics) have the potential to reveal 
critical information regarding HF pathophysiology. For example, Lin et al. used three 
different techniques to target multiple biomolecules and found a large number of 
differentially expressed genetic, proteomic and metabolic markers in end-stage HF patients’ 
blood  compared to healthy controls [152].   Another important aspect for HF biomarker 
discovery is to establish biomarkers that can distinguish HFpEF from HFrEF.  
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The current diagnosis for HFpEF relies on LVEF measured by echocardiogram [38]. 
Studies focus on distinguishing the biomarker profile between HFpEF and HFrEF emerge 
during the recent years [153-157]. Serval biomarkers have been identified to have the 
potential to differentiate HFpEF from HFrEF. The establishment of HFpEF/HFrEF specific 
biomarkers can facilitate the development of personalized treatment for HF. A study that 
involves a large patient cohort with more comprehensive HF stages (including asymptotic 
patients) that apply the same concept would be enormously beneficial to fully understand the 
biological mechanisms underlying HF and reveal potential biomarkers for diagnostic and 
prognostic purposes. In the next 5 years, we anticipate that the identification of biomolecules 
that can be easily obtained by “spitting“ into a cup or a tube would be reality for screening 
and monitoring HF in individuals within our broader community. 
 
Key Issues 
1. Heart Failure (HF) is the inability of the heart to pump sufficient blood to the body. 
2. HF affects over 23 million people worldwide, with prevalence in the western world of 
approximately 1-2%. 
3. Current diagnostic methods for HF heavily rely on clinical imaging techniques and 
invasive blood sampling. Unspecific clinical symptoms make current methods even 
more problematic for use in early screening of HF. 
4. Novel HF biomarkers have been established in urine and saliva. Due to the relative 
ease of collecting urine/saliva samples, these biomarkers are ideal for developing an 
early screening test for HF. 
5. Studies of proteomic and genetic profiles in HF patients have revealed novel 
biomarkers that have the potential to be translated into clinical settings. 
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6. Large multicentre clinical studies need to be conducted to evaluate the utility of these 
novel biomarkers. 
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